AC-083 / J&J - LARVOL DELTA

ES-QuERI: Eisenmenger Quality Enhancement Research Initiative (clinicaltrials.gov) - P=N/A; N=200; Active, not recruiting; Sponsor: Actelion; Recruiting ➔ Active, not recruiting; Trial primary completion date: Dec 2018 ➔ Apr 2018

Enrollment closed • Trial primary completion date • Biosimilar

Eisenmenger Syndrome in the Nordic Countries (clinicaltrials.gov) - P=N/A; N=714; Active, not recruiting; Sponsor: Rigshospitalet, Denmark; Recruiting ➔ Active, not recruiting; N=1000 ➔ 714

Enrollment change • Enrollment closed • Biosimilar

First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders (clinicaltrials.gov) - P1; N=72; Recruiting; Sponsor: Actelion; Active, not recruiting ➔ Recruiting; N=48 ➔ 72

Enrollment change • Enrollment open • Biosimilar

Eisenmenger Quality Enhancement Research Initiative (clinicaltrials.gov) - P=N/A; N=200; Recruiting; Sponsor: Actelion; Trial primary completion date: Mar 2015 ->Dec 2018

Trial primary completion date • Biosimilar